{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:30:46Z","timestamp":1791862246173,"version":"4.3.4"},"reference-count":6,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:p>This cross-sectional study evaluates the duration between application to US Food and Drug Administration (FDA) and approval for new drugs and biologics in the US from 2015 to 2022.<\/jats:p>","DOI":"10.1001\/jamanetworkopen.2023.31753","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T15:53:17Z","timestamp":1693497197000},"page":"e2331753","source":"Crossref","is-referenced-by-count":14,"title":["Use of Expedited Regulatory Programs and Clinical Development Times for FDA-Approved Novel Therapeutics"],"prefix":"10.1001","volume":"6","author":[{"given":"Alissa K.","family":"Wong","sequence":"first","affiliation":[{"name":"Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Mooghali","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Yale Collaboration for Regulatory Rigor, Integrity and Transparency, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshma","family":"Ramachandran","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Yale Collaboration for Regulatory Rigor, Integrity and Transparency, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Yale Collaboration for Regulatory Rigor, Integrity and Transparency, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut"},{"name":"Center for Outcomes Research and Evaluation, Yale-New Haven Health System, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Wallach","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"issue":"21","key":"zld230162r2","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1001\/jama.2017.14896","article-title":"The FDA\u2019s expedited programs and clinical development times for novel therapeutics, 2012-2016.","volume":"318","author":"Hwang","year":"2017","journal-title":"JAMA"},{"issue":"11","key":"zld230162r3","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/d41573-021-00190-9","article-title":"Clinical development times for innovative drugs.","volume":"21","author":"Brown","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"zld230162r4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.3284","article-title":"Assessment of clinical trials supporting US Food and Drug Administration approval of novel therapeutic agents, 1995-2017.","volume":"3","author":"Zhang","year":"2020","journal-title":"JAMA Netw Open"},{"key":"zld230162r5","doi-asserted-by":"publisher","first-page":"k2031","DOI":"10.1136\/bmj.k2031","article-title":"Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.","volume":"361","author":"Wallach","year":"2018","journal-title":"BMJ"},{"key":"zld230162r6","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-018-4779-x","article-title":"Timeliness of postmarket studies for new pharmaceuticals approved between 2009 and 2012: a cross-sectional analysis.","volume":"34","author":"Wallach","year":"2019","journal-title":"J Gen Intern Med"},{"key":"zld230162r1","unstructured":"US Food and Drug Administration. Expedited programs for serious conditions: drugs and biologics. Accessed May 10, 2023. https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM358301.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2808944\/wong_2023_ld_230162_1692815145.98575.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T15:53:20Z","timestamp":1693497200000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2808944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":6,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.31753","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,31]]}}}